# Margitta Worm

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/margitta-worm/

## Facts

| Field | Value |
| --- | --- |
| Citations | 43,615 |
| Field | Food Allergy and Anaphylaxis Research |
| h-index | 100 |
| i10-index | 523 |
| Last Known Institution | Freie Universität Berlin |
| OpenAlex ID | https://openalex.org/A5048797041 |
| ORCID iD | 0000-0002-3449-1245 |
| Works | 1,131 |

## Researcher papers

Showing 12 of 21.

- [Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis](https://scholariq.org/papers/two-phase-3-trials-of-dupilumab-versus-placebo-in-atopic-dermatitis/)
- [EAACI Food Allergy and Anaphylaxis Guidelines: diagnosis and management of food allergy](https://scholariq.org/papers/eaaci-food-allergy-and-anaphylaxis-guidelines-diagnosis-and-management-of-food/)
- [World Allergy Organization Anaphylaxis Guidance 2020](https://scholariq.org/papers/world-allergy-organization-anaphylaxis-guidance-2020/)
- [Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology](https://scholariq.org/papers/anaphylaxis-guidelines-from-the-european-academy-of-allergy-and-clinical/)
- [EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis](https://scholariq.org/papers/eaaci-guidelines-on-allergen-immunotherapy-allergic-rhinoconjunctivitis/)
- [Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*](https://scholariq.org/papers/tralokinumab-for-moderate-to-severe-atopic-dermatitis-results-from-two-52-week/)
- [Anaphylaxis in children and adolescents: The European Anaphylaxis Registry](https://scholariq.org/papers/anaphylaxis-in-children-and-adolescents-the-european-anaphylaxis-registry/)
- [EAACI guidelines: Anaphylaxis (2021 update)](https://scholariq.org/papers/eaaci-guidelines-anaphylaxis-2021-update/)
- [2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines](https://scholariq.org/papers/2015-update-of-the-evidence-base-world-allergy-organization-anaphylaxis/)
- [Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-in-adults-with-moderate-to-severe-atopic/)
- [The epidemiology of anaphylaxis in Europe: a systematic review](https://scholariq.org/papers/the-epidemiology-of-anaphylaxis-in-europe-a-systematic-review/)
- [<scp>EAACI</scp> guidelines on the diagnosis of <scp>IgE</scp>‐mediated food allergy](https://scholariq.org/papers/scp-eaaci-scp-guidelines-on-the-diagnosis-of-scp-ige-scp-mediated-food-allergy/)

## Researcher topics

- [Food Allergy and Anaphylaxis Research](https://scholariq.org/topics/food-allergy-and-anaphylaxis-research/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Contact Dermatitis and Allergies](https://scholariq.org/topics/contact-dermatitis-and-allergies/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)

## Researcher university

- [Freie Universität Berlin](https://scholariq.org/institutions/freie-universitat-berlin/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.